AMEX · VNRX
VolitionRX Ltd
Healthcare · Medical - Devices
$0.21▼ 3.69% ($0.01)at close
After hours$0.21▲ 0.24%7:32 PM ET
Market cap
$1.76M
P/E
N/M
EPS (TTM)
-$2.80
Next earnings
Nov 12, 2026
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price needs 6.3% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
That's below its past 4-year pace of 109.3%.
Value per share
Base case
$5.02
Price used $0.21 is 96% below this
USD · TTM ending Jun 30, 2026 · Price Oct 9, 8:00 PM UTC
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
1 more note
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
Revenue each value needs
Revenue today $2.5M. The price needs $4.5M by 2036. Base case: $14.7M. At its recent pace: $4B. Bear to Bull: $9.2M to $21.9M.
Revenue today $2.5M. The price needs $4.5M by 2036. Base case: $14.7M. At its recent pace: $4B. Bear to Bull: $9.2M to $21.9M.
Revenue in 2036
today $2.5M
−$10.2Mless than the Base case
Value per share · Base case
$5.02
Price $0.21
96% below this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 13.6%
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
1 more note
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
USD · TTM ending Jun 30, 2026 · Price Oct 9, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 98.24% over the last year. Revenue grew 86.32% over the trailing twelve months. Operating margin moved from -1,779.01% to -786.69%. Free cash flow grew 10.86% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -786.69%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
Market multiples
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
5
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 12, 2026
Q3 FY26 · EPS est -$0.35 · Revenue est $706.44K
View
Institutional Sentiment
VolitionRX Ltd · VNRX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.